Respiratory investigation最新文献

{"title":"Impact of hospitalization on health-related quality of life in patients receiving home oxygen therapy: Insights of the Japanese white paper on home respiratory care 2024","authors":"Satoshi Hamada ,&nbsp;Jun Ueki ,&nbsp;Toyohiro Hirai ,&nbsp;Emika Sano ,&nbsp;Keiko Hino ,&nbsp;Megumi Ikeda ,&nbsp;Susumu Sato ,&nbsp;Toru Oga ,&nbsp;Tomomasa Tsuboi ,&nbsp;Hajime Kurosawa ,&nbsp;Hiroo Wada ,&nbsp;the Japanese White Paper on Home Respiratory Care 2024 working group","doi":"10.1016/j.resinv.2025.101341","DOIUrl":"10.1016/j.resinv.2025.101341","url":null,"abstract":"<div><h3>Background</h3><div>There are no available data on the impact of hospitalization on health-related quality of life (HRQoL) in patients receiving home oxygen therapy (HOT). Thus, the present study aimed to examine the association between hospitalization and HRQoL in patients receiving HOT based on the results of the Japanese White Paper on Home Respiratory Care 2024.</div></div><div><h3>Methods</h3><div>Patients receiving HOT who completed the HRQoL section of the patient survey, assessed using the Short Form-8 (SF-8) questionnaire, were included in the analysis. This survey data were collected from December 2021 to March 2023. The SF-8 questionnaire comprised eight subitems and two summary scores (physical component summary [PCS] and mental component summary [MCS]). Hospitalization within the past year were evaluated, excluding those due to coronavirus disease 2019.</div></div><div><h3>Results</h3><div>Totally, 288 patients receiving HOT were examined. In the SF-8 questionnaire survey, all items except body pain and the two summary scores did not differ between patients with chronic obstructive pulmonary disease and those with interstitial lung disease. Patients who had history of hospitalization had lower scores in all eight subitems and in both summary scores than those who did not. Based on a stepwise multiple linear regression analysis, PCS (β = −0.14, p = 0.011) and MCS (β = −0.14, p = 0.014) scores were independently and negatively correlated with hospitalization.</div></div><div><h3>Conclusions</h3><div>A history of hospitalization was independently associated with reduced HRQoL in patients receiving HOT. Prospective studies are needed to clarify underlying mechanisms and to evaluate interventions that may minimize HRQoL decline.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101341"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and clinical features of venous thromboembolism in patients with lung cancer in Japan: results from the CS-Lung-003 prospective observational registry study","authors":"Yukari Tsubata ,&nbsp;Nobuhiro Kanaji ,&nbsp;Mika Nakao ,&nbsp;Takeshi Masuda ,&nbsp;Masahiro Yamasaki ,&nbsp;Masahiro Kodani ,&nbsp;Nobuhisa Ishikawa ,&nbsp;Toshiyuki Kozuki ,&nbsp;Masaaki Inoue ,&nbsp;Kazuya Nishii ,&nbsp;Katsuyuki Hotta ,&nbsp;Katsuyuki Kiura ,&nbsp;Takeshi Isobe","doi":"10.1016/j.resinv.2025.11.011","DOIUrl":"10.1016/j.resinv.2025.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Venous thromboembolism (VTE) is a frequent complication of cancer-associated thrombosis, and its management is critical when considering cancer treatment selection and prognosis. The aim of this study was to investigate the incidence and risk factors for VTE in patients with lung cancer using the CS-Lung003 platform, a multicenter prospective observational study of advanced lung cancer.</div></div><div><h3>Methods</h3><div>Patients with a pathologic diagnosis of lung cancer at any stage were included. The incidence of VTE was calculated using the CS-Lung003 database, and risk factors were examined using logistic regression analysis.</div></div><div><h3>Results</h3><div>The analysis included 1744 patients (80 % male). Sixty patients (3.4 %) had VTE at/after enrollment in the CS-Lung003 trial. The median age was 69 years (range 63–76) in the group without VTE and 72 years (range 67–77) in the group with VTE. Adenocarcinoma was diagnosed in 58.7 % of patients in the group without VTE and 46.7 % in the group with VTE. Univariate analysis revealed male sex, body weight, and hypertension as risk factors for VTE. Overall survival was 29.1 months in the group without VTE and 30.6 months in the group with VTE. Among patients with stage IIIB–IV, the VTE group showed significantly longer overall survival compared with the non-VTE group (p = 0.041).</div></div><div><h3>Conclusions</h3><div>The incidence of VTE in this study was low, suggesting that there may have been patients with VTE complications that were not reported in the registry. In addition, most patients with VTE received therapeutic intervention; appropriate diagnosis and treatment may have allowed cancer treatment to continue. Appropriate diagnosis and treatment of VTE might allow lung cancer therapy continuation without compromising survival.</div></div><div><h3>Clinical trial registry/registration number</h3><div>UMIN-CTR/UMIN000026696.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101332"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological palliative care for patients with interstitial lung disease in Japan: A secondary analysis of a National Survey of Japanese Respiratory Physicians","authors":"Yoshinobu Matsuda ,&nbsp;Tomoyuki Fujisawa ,&nbsp;Tatsuya Morita ,&nbsp;Masanori Mori ,&nbsp;Norimichi Akiyama ,&nbsp;Takafumi Koyauchi ,&nbsp;Mitsunori Miyashita ,&nbsp;Ryo Tachikawa ,&nbsp;Keisuke Tomii ,&nbsp;Hiromi Tomioka ,&nbsp;Satoshi Hagimoto ,&nbsp;Yasuhiro Kondoh ,&nbsp;Yoshikazu Inoue ,&nbsp;Takafumi Suda","doi":"10.1016/j.resinv.2025.11.009","DOIUrl":"10.1016/j.resinv.2025.11.009","url":null,"abstract":"<div><h3>Background</h3><div>Patients with interstitial lung disease (ILD) often experience psychological symptoms. This study aimed to clarify the status of psychological support for patients with ILD in Japan.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis on a nationwide survey of Japanese respiratory physicians to assess psychological support availability, consultation departments, reasons for palliative care referrals, and opinions on insurance coverage for psychologist-led psychotherapy.</div></div><div><h3>Results</h3><div>Of 1332 respondents, 1023 managed patients with ILD in the previous year. Among them, 34.5 % reported no psychological support availability and 42.9 % reported insufficient support. Psychiatry or psychosomatic medicine departments were consulted by 77.3 %, and palliative care teams by 52.2 %. Anxiety (47.4 %) and depression (44.6 %) were the reasons for palliative care referral. Overall, 93.6 % considered insurance coverage for psychologist-led psychotherapy helpful or essential.</div></div><div><h3>Conclusions</h3><div>Most physicians lack adequate psychological support resources for ILD despite frequent psychological symptoms. Systematic development of support structures and insurance coverage are needed.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101330"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of individuals with COPD using biometric voice and cough sound features","authors":"Yasushi Obase ,&nbsp;Susumu Fukahori ,&nbsp;Jun Iriki ,&nbsp;Takahiro Takazono ,&nbsp;Yusei Tsukamoto ,&nbsp;Shinnosuke Takemoto ,&nbsp;Noriho Sakamoto ,&nbsp;Yusuke Hamanaka ,&nbsp;Hideaki Watanabe ,&nbsp;Kazumi Hirano ,&nbsp;Chizu Fukushima ,&nbsp;Tomoya Nishino ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.resinv.2025.101353","DOIUrl":"10.1016/j.resinv.2025.101353","url":null,"abstract":"<div><h3>Background</h3><div>Chronic obstructive pulmonary disease (COPD), a major global health burden linked to smoking, is frequently underdiagnosed due to low awareness and delayed symptom recognition. This study explored the feasibility of non-invasive voice and cough sound analysis for COPD identification.</div></div><div><h3>Methods</h3><div>In this prospective study, 55 participants (26 with COPD, 29 without) underwent pulmonary function testing and provided sociodemographic and clinical data. Speech and cough sounds were recorded three times per participant and processed using acoustic feature extraction, feature selection via the minimum redundancy maximum relevance algorithm, and logistic regression classification. Model performance was evaluated using four-fold cross-validation. Statistical analysis was conducted with JMP software (p &lt; 0.05).</div></div><div><h3>Results</h3><div>The vowel sound/u/showed statistically significant discriminatory ability in the mixed-gender cohort, but sensitivity and specificity were both below 80 %, indicating limited diagnostic performance. When restricted to male participants, both metrics exceeded 80 %, suggesting higher discriminatory power. Smartphone recordings yielded comparable accuracy to integrated circuit recorders. Adding COPD assessment test scores and smoking history did not improve classification.</div></div><div><h3>Conclusions</h3><div>Voice analysis may offer a non-invasive screening approach for COPD. However, this study was limited to male participants and a single disease target, restricting generalizability. Future research will expand to include related respiratory conditions such as bronchiectasis and assess performance across sexes and disease types.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101353"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical features of Mycobacterium abscessus complex and Mycobacterium kansasii pulmonary disease in Kyushu, Japan","authors":"Kazuaki Takeda ,&nbsp;Takahiro Takazono ,&nbsp;Shotaro Ide ,&nbsp;Masataka Yoshida ,&nbsp;Naoki Iwanaga ,&nbsp;Naoki Hosogaya ,&nbsp;Yusei Tsukamoto ,&nbsp;Satoshi Irifune ,&nbsp;Takayuki Suyama ,&nbsp;Asuka Umemura ,&nbsp;Tomo Mihara ,&nbsp;Akira Kondo ,&nbsp;Tsutomu Kobayashi ,&nbsp;Eisuke Sasaki ,&nbsp;Toyomitsu Sawai ,&nbsp;Yasuhito Higashiyama ,&nbsp;Kohji Hashiguchi ,&nbsp;Minako Hanaka ,&nbsp;Toshihiko Ii ,&nbsp;Kiyoyasu Fukushima ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.resinv.2025.101358","DOIUrl":"10.1016/j.resinv.2025.101358","url":null,"abstract":"<div><h3>Background</h3><div>Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic respiratory infection with a growing incidence and mortality globally. Although the clinical features, treatment, and prognosis of <em>Mycobacterium avium-intracellulare</em> (MAI) pulmonary disease have been extensively reported, evidence regarding non-MAI NTM-PD remains limited.</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients newly diagnosed with NTM-PD between 2010 and 2017 at 18 hospitals in Kyushu, Japan. Data on baseline characteristics, causative organisms, radiological findings, treatment regimens, and clinical outcomes were collected and analysed.</div></div><div><h3>Results</h3><div>In total, 1317 patients were enrolled. <em>M. intracellulare</em> (50.4 %), <em>M. avium</em> (40.5 %), <em>M. abscessus</em> complex (MABC) (2.4 %), and <em>M. kansasii</em> (2.4 %) were identified as the major causative organisms. Compared with patients with MAI, those with MABC exhibited a lower body mass index and a higher AFB sputum smear positivity rate. Patients with <em>M. kansasii</em> infection were predominantly male, frequently had underlying chronic obstructive pulmonary disease, and presented with cavitary lesions. Treatment initiation rates for MABC and <em>M. kansasii</em> were 71.9 % and 87.5 %, respectively. The response rate to the treatment in sputum mycobacterial evaluation was comparable between the two groups. However, the re-treatment rate was higher in the MABC group (30.4 % vs. 14.3 %). The 10-year mortality rates were 25.0 % and 15.6 % for MABC and <em>M. kansasii</em>, respectively.</div></div><div><h3>Conclusions</h3><div>Initial treatment responses for MABC and <em>M. kansasii</em> were favourable. However, long-term outcomes for MABC remained poor, potentially owing to the limited availability of effective continuation-phase therapies. Further large-scale prospective studies are warranted to understand the clinical management and prognosis of non-MAI NTM-PD.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101358"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of ultrasound-guided cervical lymph node biopsy in lung cancer: A scoping review","authors":"L. Thong ,&nbsp;C. Daneshvar ,&nbsp;M. Hassan ,&nbsp;D. Breen","doi":"10.1016/j.resinv.2025.11.010","DOIUrl":"10.1016/j.resinv.2025.11.010","url":null,"abstract":"<div><div>The involvement of cervical lymph nodes in lung cancer occurs frequently. Despite the involvement of this group of lymph nodes reflecting either stage N3 or M1b in patients with non-small cell lung cancer, they do not receive the same amount of attention as mediastinal lymph nodes. Furthermore, these lymph nodes are more accessible for histology samples compared to other group of lymph nodes. Critically, cervical lymph nodes are often missed on CT scans. Neck US and US-guided biopsy of cervical lymph nodes have more established roles in other primary malignancies (e.g. thyroid cancer) and non-malignant diseases. This scoping review explores existing literature on neck US and cervical lymph node biopsy in patients with suspected lung cancer. The role and potentials benefits of neck US and cervical lymph node biopsy in this group of patients is examined. We also explored whether the procedure is being performed routinely by respiratory physicians as part of their lung cancer algorithm.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101331"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145532471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BAL cells analysis and lung function parameters in fibrotic hypersensitivity pneumonitis at baseline and in relation to survival","authors":"Punchalee Kaenmuang ,&nbsp;Fiammetta Danzo ,&nbsp;Simon Bax ,&nbsp;Richard J. Hewitt ,&nbsp;Maria Kokosi ,&nbsp;Vasileios Kouranos ,&nbsp;Felix Chua ,&nbsp;Peter M. George ,&nbsp;Gisli Jenkins ,&nbsp;Athol U. Wells ,&nbsp;Carmel JW. Stock ,&nbsp;Piersante Sestini ,&nbsp;Elisabetta A. Renzoni","doi":"10.1016/j.resinv.2025.101359","DOIUrl":"10.1016/j.resinv.2025.101359","url":null,"abstract":"<div><div>In fibrotic hypersensitivity pneumonitis, the relevance of bronchoalveolar lavage (BAL) lymphocytosis remains unclear. We investigated the relationship between BAL %lymphocytes, baseline pulmonary function tests (PFTs) and transplant-free survival. We retrospectively analysed 162 treatment-naïve patients (median age 64 years; 43 % male; 39 % ever-smokers) undergoing BAL within three months of PFTs. Mean FVC 79 %, DLCO 43 %, composite physiologic index (CPI) 48. Median BAL lymphocytes were 24 %(IQR 21–28). BAL %lymphocytes were associated with less severe disease, FVC [coefficient 0.28 (95 %C.I. 0.06–0.48), p = 0.01], FEV₁ [0.20(0.0002–0.41), p = 0.05], and CPI [-0.11(-0.21 to −0.01, p = 0.04]. Although BAL% lymphocytes were not correlated with DLCO, significant opposite correlations were observed for its two components: positive with VA% [0.32 (0.18–0.45), p &lt; 0.0005]; negative with KCO% [-0.37(-0.51 to −0.23), p &lt; 0.0005<strong>].</strong> In adjusted Cox regression models, BAL %lymphocytes, lower CPI, higher %FVC, %FEV₁ and %DLCO were significantly associated with increased survival. These findings suggest BAL lymphocytosis reflects a pathophysiological pattern linked to better outcomes.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101359"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145883568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to choose a biologic agent considering comorbidities of bronchial asthma","authors":"Masamichi Itoga,&nbsp;Sadatomo Tasaka","doi":"10.1016/j.resinv.2025.101337","DOIUrl":"10.1016/j.resinv.2025.101337","url":null,"abstract":"<div><div>Biologic therapies have revolutionized the treatment of severe asthma. However, the selection of the optimal biologic agent remains challenging because of the heterogeneity of disease phenotypes and frequent comorbidities. This mini-review explored the clinical relevance of comorbidities in the selection of biologics for patients with asthma.</div><div>Herein, we summarize recent evidence on the prevalence of comorbidities associated with type 2 inflammation, including chronic spontaneous urticaria, atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, eosinophilic otitis media, aspirin-exacerbated respiratory disease, allergic rhinitis, allergic bronchopulmonary mycosis, obesity, and chronic obstructive pulmonary disease, and review the efficacy of five major biologics (omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab) in these settings. Each biologic targets distinct immunologic pathways in type 2 inflammation, including IgE, IL-5, IL-5Rα, IL-4Rα, and thymic stromal lymphopoietin, respectively.</div><div>In conclusion, the assessment of comorbidities in addition to biomarkers is essential for tailoring biologic therapies for severe asthma. Integrating comorbidity profiles into treatment strategies allows for a more precise and effective use of biologics, ultimately improving outcomes in complicated asthma cases.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101337"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145616019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oscillometrically assessed higher respiratory reactance is associated with impaired lung function and poorer prognosis in patients with fibrotic idiopathic interstitial pneumonias","authors":"Yuya Yamamoto ,&nbsp;Taisuke Akamatsu ,&nbsp;Keita Hirai ,&nbsp;Toshihiro Shirai","doi":"10.1016/j.resinv.2025.101352","DOIUrl":"10.1016/j.resinv.2025.101352","url":null,"abstract":"<div><h3>Background</h3><div>Fibrotic idiopathic interstitial pneumonias (IIPs) are progressive lung diseases with variable prognoses. Oscillometry, a non-invasive method for assessing respiratory impedance, has emerged as a potential tool for disease stratification. However, the association between standardized respiratory reactance (Xrs) measured by oscillometry and clinical outcomes in IIPs, including those other than idiopathic pulmonary fibrosis, remains unclear. Therefore, we investigated this association.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 101 patients with fibrotic IIPs treated at Shizuoka General Hospital from 2017 to 2022. Fibrosis was defined by high-resolution computed tomography findings of honeycombing, traction bronchiectasis, or subpleural reticulation. Patients were categorized into high-Xrs or low-Xrs groups based on whether Xrs parameters (X5, Fres, or AX) exceeded 1.64 standard deviations above Japanese standard values. The primary outcome was mortality. Cox proportional hazards analysis identified prognostic factors.</div></div><div><h3>Results</h3><div>Among 101 patients, 25 (24.8 %) were classified as high-Xrs. Median overall survival was significantly shorter in the high-Xrs group (21.1 months; 95 % CI, 13.2–43.3) compared to the low-Xrs group (78.7 months; 95 % CI, 56.8–not reached). A subgroup analysis of IPF and non-IPF patients showed significant survival differences between the high-Xrs and low-Xrs groups. Multivariate analysis identified low %FVC and high-Xrs classification as independent predictors of mortality.</div></div><div><h3>Conclusions</h3><div>High respiratory reactance measured by oscillometry was independently associated with impaired lung function and poor prognosis in patients with fibrotic IIPs. Oscillometry may be a valuable tool for risk stratification and prognostic assessment in this patient population.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101352"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of atropine and hydroxyzine pretreatment in contemporary bronchoscopy","authors":"Kazuo Tsuchiya,&nbsp;Ryota Miyamoto,&nbsp;Tomo Tsunoda,&nbsp;Taisuke Ito,&nbsp;Takuro Akashi,&nbsp;Yoshiyuki Oyama,&nbsp;Masaki Ikeda","doi":"10.1016/j.resinv.2025.11.012","DOIUrl":"10.1016/j.resinv.2025.11.012","url":null,"abstract":"<div><h3>Background</h3><div>Bronchoscopy is essential for diagnosing and managing respiratory diseases. However, secretions and airway reflexes can impair procedural quality and patient comfort. While anticholinergic pretreatment using agents such as atropine and hydroxyzine has historically mitigated these physiological responses, recent guidelines discourage their routine use because of concerns regarding hemodynamic changes and uncertain benefits. This study aimed to assess the efficacy of anticholinergic pretreatment during contemporary bronchoscopy.</div></div><div><h3>Methods</h3><div>We conducted a single-center, cross-sectional study comparing two cohorts of patients who underwent bronchoscopy with transbronchial and ultrasound-guided needle biopsies. Group A (n = 35) received pretreatment with intramuscular atropine (0.5 mg) and hydroxyzine (25 mg) between July 2022 and September 2023, while Group B (n = 35) underwent procedures without pretreatment between December 2024 and March 2025. Patient discomfort was evaluated using a visual analog scale. Propensity score adjustment with inverse probability of treatment weighting (IPTW) accounted for differences in baseline factors.</div></div><div><h3>Results</h3><div>Seventy patients were included (n = 35 per group). After IPTW adjustment, Group B reported greater distress from salivation and cough and lower willingness for repeat bronchoscopy (p = 0.03, p = 0.02, p = 0.001, respectively). Group B also showed higher use of lidocaine (<em>p</em> &lt; 0.001). No significant differences in midazolam dosage or vital signs were observed among either group.</div></div><div><h3>Conclusion</h3><div>Anticholinergic pretreatment may reduce procedural discomfort, particularly that associated with secretions and airway reflexes, without evident adverse effects. Further randomized controlled trials are required to validate the role of pretreatment in contemporary bronchoscopy.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"64 1","pages":"Article 101333"},"PeriodicalIF":2.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}